Compare Johnson & Johnson (JNJ) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Lemonade Inc — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Lemonade Inc trades at $46.5 (market cap $3.63B). The key difference: Johnson & Johnson is far larger — about 170.3× Lemonade Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Lemonade Inc for 27 Days on average.
| JNJ | LMND | |
|---|---|---|
Market Cap | $618.09B | $3.63B |
Volume | 6,050,983 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $278.43 | $96.57 |
52-Week Low | $186.00 | $43.91 |
Typical Hold Time | 129 Days | 27 Days |
Enterprise Value | $646.37B | $3.49B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
LMND trades at $46.46, down 0.79% on the day, with a bearish technical signal and key resistance at $48. Revenue growth is strong, rising to $738 million in 2025, but the company remains unprofitable with a net margin of -22.43%. Recent news highlights expansion into new states and AI-driven efficiency gains, targeting EBITDA profitability by late 2026.
The outlook balances high growth potential against persistent losses. Analyst consensus is divided with a $67 price target suggesting upside, but execution risks and competitive pressures remain key concerns. The path to profitability is the critical catalyst for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
